Contact

All Stories

  1. Past and Present Perspectives on β-Lactamases

    Article • Antimicrobial Agents and Chemotherapy, July 2018, ASM Journals

    Dr. Karen Bush

  2. Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam

    Article • Antimicrobial Agents and Chemotherapy, May 2017, ASM Journals

    Dr. Karen Bush

  3. In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

    Article • Antimicrobial Agents and Chemotherapy, December 2014, ASM Journals

    Dr. Karen Bush, Wright Nichols

  4. In Vitro Activity of Ceftolozane-Tazobactam as Determined by Broth Dilution and Agar Diffusion Assays against Recent U.S. Escherichia coli Isolates from 2010 to 2011 Carrying CTX-M-Type Extended-Spectrum  -Lactamases

    Article • Journal of Clinical Microbiology, August 2014, ASM Journals

    Dr. Karen Bush

  5. β-Lactam Resistance in the 21st Century

    Article • April 2014, ASM Journals

    Dr. Karen Bush

  6. β-Lactamases: Historical Perspectives

    Article • April 2014, ASM Journals

    Dr. Karen Bush

  7. Cautious Optimism for the Antibacterial Pipeline

    Article • Microbe Magazine, April 2014, ASM Journals

    Dr. Karen Bush

  8. Investigational Antimicrobial Agents of 2013

    Article • Clinical Microbiology Reviews, October 2013, ASM Journals

    Dr. Karen Bush

  9. Carbapenemases: Partners in crime

    Article • Journal of Global Antimicrobial Resistance, March 2013, Elsevier

    Dr. Karen Bush

  10. Proliferation and significance of clinically relevant β‐lactamases

    Article • Annals of the New York Academy of Sciences, January 2013, Wiley

    Dr. Karen Bush

  11. The ABCD’s of β-lactamase nomenclature

    Article • Journal of Infection and Chemotherapy, January 2013, Elsevier

    Dr. Karen Bush

  12. Introduction to Antimicrobial Therapeutics Reviews: The bacterial cell wall as an antimicrobial target

    Article • Annals of the New York Academy of Sciences, January 2013, Wiley

    Dr. Karen Bush

  13. Detection systems for carbapenemase gene identification should include the SME serine carbapenemase

    Article • International Journal of Antimicrobial Agents, January 2013, Elsevier

    Dr. Karen Bush

  14. Improving known classes of antibiotics: an optimistic approach for the future

    Article • Current Opinion in Pharmacology, October 2012, Elsevier

    Dr. Karen Bush

  15. Introduction to Antimicrobial Therapeutics Reviews

    Article • Annals of the New York Academy of Sciences, December 2011, Wiley

    Dr. Karen Bush

  16. New antimicrobial agents on the horizon

    Article • Biochemical Pharmacology, December 2011, Elsevier

    Dr. Karen Bush

  17. Evolution of β-Lactamases: Past, Present, and Future

    Article • November 2011, Springer Science + Business Media

    Dr. Karen Bush

  18. Tackling antibiotic resistance

    Article • Nature Reviews Microbiology, November 2011, Springer Science + Business Media

    Dr. Karen Bush

  19. Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria

    Article • Annual Review of Microbiology, October 2011, Annual Reviews

    Dr. Karen Bush

  20. The coming of age of antibiotics: discovery and therapeutic value

    Article • Annals of the New York Academy of Sciences, December 2010, Wiley

    Dr. Karen Bush

  21. Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457

    Article • International Journal of Antimicrobial Agents, November 2010, Elsevier

    Dr. Karen Bush

  22. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae

    Article • Current Opinion in Microbiology, October 2010, Elsevier

    Dr. Karen Bush

  23. New β-lactam antibiotics and β-lactamase inhibitors

    Article • Expert Opinion on Therapeutic Patents, September 2010, Informa Healthcare

    Dr. Karen Bush

  24. Inhibition of metallo-β-lactamases by pyridine monothiocarboxylic acid analogs

    Article • The Journal of Antibiotics, March 2010, Springer Science + Business Media

    Dr. Karen Bush

  25. β-Lactam antibiotics

    Article • January 2010, Elsevier

    Dr. Karen Bush

  26. Other β-lactam antibiotics

    Article • January 2010, Elsevier

    Dr. Karen Bush

  27. Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram-negative infections

    Article • Critical Care, January 2010, Springer Science + Business Media

    Dr. Karen Bush

  28. Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones

    Article • Bioorganic & Medicinal Chemistry Letters, September 2009, Elsevier

    Dr. Karen Bush

  29. Molecular characterisation of meticillin-resistant Staphylococcus aureus isolates from two ceftobiprole Phase 3 complicated skin and skin-structure infection clinical trials

    Article • International Journal of Antimicrobial Agents, August 2009, Elsevier

    Dr. Karen Bush, Dr Michael R Jacobs

  30. The Importance of β-Lactamases to the Development of New β-Lactams

    Article • January 2009, Springer Science + Business Media

    Dr. Karen Bush

  31. Casting a broader net for approaches to antibacterial research and development

    Article • Current Opinion in Biotechnology, December 2008, Elsevier

    Dr. Karen Bush

  32. Effects of the 7-Valent Pneumococcal Conjugate Vaccine on U.S. Levofloxacin-Resistant Streptococcus pneumoniae

    Article • Microbial Drug Resistance, September 2008, Mary Ann Liebert Inc

    Dr. Karen Bush

  33. The Evolution of β‐Lactamases

    Article • September 2007, Wiley

    Dr. Karen Bush

  34. Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives

    Article • Bioorganic & Medicinal Chemistry Letters, July 2007, Elsevier

    Dr. Karen Bush

  35. Streptogramins and Oxazolidinones

    Article • June 2007, Taylor & Francis

    Dr. Karen Bush

  36. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy

    Article • Expert Opinion on Investigational Drugs, March 2007, Informa Healthcare

    Dr. Karen Bush

  37. Preparation of Erythromycin Analogues Having Functional Groups at C‐15.

    Article • ChemInform, January 2007, Wiley

    Dr. Karen Bush

  38. Synthesis and antibacterial activity of C6-carbazate ketolides

    Article • Bioorganic & Medicinal Chemistry Letters, December 2006, Elsevier

    Dr. Karen Bush

  39. Antibacterial activity of pyrrolopyridine-substituted oxazolidinones: synthesis and in vitro SAR of various C-5 acetamide replacements

    Article • Bioorganic & Medicinal Chemistry Letters, September 2006, Elsevier

    Dr. Karen Bush

  40. Synthesis and Antibacterial Activity of 6‐O‐Heteroarylcarbamoyl‐11,12‐lactoketolides.

    Article • ChemInform, July 2006, Wiley

    Dr. Karen Bush

  41. Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides

    Article • Bioorganic & Medicinal Chemistry Letters, April 2006, Elsevier

    Dr. Karen Bush

  42. Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives

    Article • Bioorganic & Medicinal Chemistry Letters, February 2006, Elsevier

    Dr. Karen Bush

  43. 15‐Amido Erythromycins: Synthesis and in vitro Activity of a New Class of Macrolide Antibiotics.

    Article • ChemInform, August 2005, Wiley

    Dr. Karen Bush

  44. _-Lactams for the Treatment of Biofilm-Associated Infections

    Article • August 2005, Taylor & Francis

    Dr. Karen Bush

  45. 15-Amido Erythromycins: Synthesis and in Vitro Activity of a New Class of Macrolide Antibiotics

    Article • The Journal of Antibiotics, March 2005, Springer Science + Business Media

    Dr. Karen Bush

  46. Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes

    Article • Bioorganic & Medicinal Chemistry Letters, February 2005, Elsevier

    Dr. Karen Bush

  47. Synthesis and Antibacterial Activity of C‐6 Carbamate Ketolides, a Novel Series of Orally Active Ketolide Antibiotics.

    Article • ChemInform, December 2004, Wiley

    Dr. Karen Bush

  48. Taking inventory: antibacterial agents currently at or beyond Phase 1

    Article • Current Opinion in Microbiology, October 2004, Elsevier

    Dr. Karen Bush

  49. The Synthesis and Antimicrobial Evaluation of a New Series of isoxazolinyl Oxazolidinones.

    Article • ChemInform, September 2004, Wiley

    Dr. Karen Bush

  50. Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics

    Article • Bioorganic & Medicinal Chemistry Letters, September 2004, Elsevier

    Dr. Karen Bush

  51. The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones

    Article • Bioorganic & Medicinal Chemistry Letters, June 2004, Elsevier

    Dr. Karen Bush

  52. Editorial Commentary: Vancomycin‐Resistant Staphylococcus aureus in the Clinic: Not Quite Armageddon

    Article • Clinical Infectious Diseases, April 2004, Oxford University Press (OUP)

    Dr. Karen Bush

  53. What do we mean by antibiotic resistance?

    Article • Expert Review of Anti-infective Therapy, April 2004, Taylor & Francis

    Dr. Karen Bush

  54. Synthesis and Antibacterial Activity of Pyrroloaryl‐Substituted Oxazolidinones.

    Article • ChemInform, March 2004, Wiley

    Dr. Karen Bush

  55. Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones

    Article • Bioorganic & Medicinal Chemistry Letters, December 2003, Elsevier

    Dr. Karen Bush

  56. Antibacterial Agents, Overview

    Article • October 2003, Wiley

    Dr. Karen Bush

  57. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

    Article • Journal of Clinical Investigation, July 2003, American Society for Clinical Investigation

    Dr. Karen Bush

  58. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

    Article • Journal of Clinical Investigation, July 2003, American Society for Clinical Investigation

    Dr. Karen Bush

  59. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding

    Article • Antiviral Research, June 2003, Elsevier

    Dr. Karen Bush

  60. Novel antibacterial agents for the treatment of serious Gram-positive infections

    Article • Expert Opinion on Investigational Drugs, March 2003, Informa Healthcare

    Dr. Karen Bush

  61. ChemInform Abstract: Novel Piperidinyloxy Oxazolidinone Antibacterial Agents. Diversification of the N‐Substituent.

    Article • ChemInform, September 2002, Wiley

    Dr. Karen Bush

  62. Novel piperidinyloxy oxazolidinone antibacterial agents. Diversification of the N -Substituent

    Article • Bioorganic & Medicinal Chemistry, July 2002, Elsevier

    Dr. Karen Bush

  63. Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae with Reduced Susceptibility to Ceftazidime

    Article • Clinical Infectious Diseases, January 2002, Oxford University Press (OUP)

    Dr. Karen Bush

  64. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201

    Article • Antiviral Research, September 2001, Elsevier

    Dr. Karen Bush

  65. Novel piperidinyloxy oxazolidinone antimicrobial agents

    Article • Bioorganic & Medicinal Chemistry Letters, July 2001, Elsevier

    Dr. Karen Bush

  66. ChemInform Abstract: The Synthesis and SAR of Rhodanines as Novel C β‐Lactamase Inhibitors.

    Article • ChemInform, December 2000, Wiley

    Dr. Karen Bush

  67. ‘Superbugs’: new antibacterials in the pipeline

    Article • Emerging Drugs, December 2000, Informa Healthcare

    Dr. Karen Bush

  68. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, October 2000, Elsevier

    Dr. Karen Bush

  69. New approaches in the treatment of bacterial infections

    Article • Current Opinion in Chemical Biology, August 2000, Elsevier

    Dr. Karen Bush

  70. ChemInform Abstract: β‐Lactamases of Increasing Clinical Importance

    Article • ChemInform, February 2000, Wiley

    Dr. Karen Bush

  71. Detection of Multiresistant Ceftazidime-Susceptible Klebsiella pneumoniae Isolates Lacking TEM-26 after Class Restriction of Cephalosporins

    Article • Microbial Drug Resistance, January 2000, Mary Ann Liebert Inc

    Dr. Karen Bush

  72. Clinical Characteristics and Molecular Epidemiology Associated with Imipenem‐Resistant Klebsiella pneumoniae

    Article • Clinical Infectious Diseases, August 1999, Oxford University Press (OUP)

    Dr. Karen Bush

  73. Bacterial enzymatic resistance: β-lactamases and aminoglycoside-modifying enzymes

    Article • Current Opinion in Microbiology, October 1998, Elsevier

    Dr. Karen Bush

  74. Metallo‐β‐Lactamases: A Class Apart

    Article • Clinical Infectious Diseases, August 1998, Oxford University Press (OUP)

    Dr. Karen Bush

  75. How β-Lactamases Have Driven Pharmaceutical Drug Discovery

    Article • January 1998, Springer Science + Business Media

    Dr. Karen Bush

  76. Crystal structures of the cadmium‐ and mercury‐substituted metallo‐β‐lactamase from Bacteroides fragilis

    Article • Protein Science, December 1997, Wiley

    Dr. Karen Bush

  77. Synthesis and structure-activity relationships of novel THF 1β-methylcarbapenems II

    Article • Bioorganic & Medicinal Chemistry Letters, December 1997, Elsevier

    Dr. Karen Bush

  78. Antimicrobial agents

    Article • Current Opinion in Chemical Biology, August 1997, Elsevier

    Dr. Karen Bush

  79. Synthesis and structure-activity relationships of novel THF 1β-methylcarbapenems

    Article • Bioorganic & Medicinal Chemistry Letters, July 1997, Elsevier

    Dr. Karen Bush

  80. Mono and bis double ester prodrugs of novel aminomethyl-THF 1β-methylcarbapenems

    Article • Bioorganic & Medicinal Chemistry Letters, July 1997, Elsevier

    Dr. Karen Bush

  81. Peptidic prodrugs of novel aminomethyl-THF 1β-methylcarbapenems

    Article • Bioorganic & Medicinal Chemistry Letters, July 1997, Elsevier

    Dr. Karen Bush

  82. Biochemical characterization of the carbapenem-hydrolyzing β-lactamase AsbM1 from Aeromonas sobria AER 14M: a member of a novel subgroup of metallo-β-lactamases

    Article • FEMS Microbiology Letters, April 1996, Oxford University Press (OUP)

    Dr. Karen Bush

  83. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases

    Article • Journal of Antimicrobial Chemotherapy, January 1995, Oxford University Press (OUP)

    Dr. Karen Bush

  84. Synthesis and release of doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate

    Article • Bioorganic & Medicinal Chemistry Letters, February 1993, Elsevier

    Dr. Karen Bush

  85. Inhibition of herpes simplex virus type 1 DNA polymerase by the natural product oosporein.

    Article • The Journal of Antibiotics, January 1992, Japan Antibiotics Research Association

    Dr. Karen Bush

  86. Substitution of lysine at position 104 or 240 of TEM-1pTZ18R .beta.-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam

    Article • Biochemistry, April 1991, American Chemical Society (ACS)

    Dr. Karen Bush

  87. Biochemical characteristics of extended broad spectrum β-lactamases

    Article • Infection, November 1989, Springer Science + Business Media

    Dr. Karen Bush

  88. Excitement in the β-lactamase arena

    Article • Journal of Antimicrobial Chemotherapy, January 1989, Oxford University Press (OUP)

    Dr. Karen Bush

  89. Effective cooling allows sonication to be used for liberation of β-lactamases from Gramnegative bacteria

    Article • Journal of Antimicrobial Chemotherapy, January 1989, Oxford University Press (OUP)

    Dr. Karen Bush

  90. Inactivation of β-lactamases from Enterobacter cloacae by monophosphams

    Article • Journal of Antimicrobial Chemotherapy, January 1988, Oxford University Press (OUP)

    Dr. Karen Bush

  91. Two new inhibitors of phospholipase A2 produced by Penicillium chermesinum. Taxonomy, fermentation, isolation, structure determination and biological properties.

    Article • The Journal of Antibiotics, January 1985, Japan Antibiotics Research Association

    Dr. Karen Bush

  92. Muraceins - Muramyl peptides produced by Nocardia orientalis as angiotensin-converting enzyme inhibitors I. Taxonomy, fermentation and biological properties.

    Article • The Journal of Antibiotics, January 1984, Japan Antibiotics Research Association

    Dr. Karen Bush

  93. Phenacein - an angiotensin-converting enzyme inhibitor produced by a streptomycete. I. Taxonomy, fermentation and biological properties.

    Article • The Journal of Antibiotics, January 1984, Japan Antibiotics Research Association

    Dr. Karen Bush

  94. Screening and Characterization of Enzyme Inhibitors as Drug Candidates

    Article • Drug Metabolism Reviews, January 1983, Taylor & Francis

    Dr. Karen Bush

  95. β-Lactamase inhibitors in perspective

    Article • Journal of Antimicrobial Chemotherapy, January 1983, Oxford University Press (OUP)

    Dr. Karen Bush

  96. Two new monobactam antibiotics produced by a Flexibacter sp. I. Taxonomy,fermentation,isolation and biological properties.

    Article • The Journal of Antibiotics, January 1983, Japan Antibiotics Research Association

    Dr. Karen Bush

  97. Activity of sulfa drugs and dihydrofolate reductase inhibitors againstCandida albicans

    Article • Cellular and Molecular Life Sciences, April 1982, Springer Science + Business Media

    Dr. Karen Bush

  98. SQ 26,180, a novel monobactam. I. Taxonomy, fermentation and biological properties.

    Article • The Journal of Antibiotics, January 1982, Japan Antibiotics Research Association

    Dr. Karen Bush

  99. EM5400, a family of monobactam antibiotics produced by Agrobacterium radiobacter. I. Taxonomy, fermentation and biological properties.

    Article • The Journal of Antibiotics, January 1982, Japan Antibiotics Research Association

    Dr. Karen Bush

  100. High-performance liquid chromatography of the topical anti-inflammatory steroid halcinonide

    Article • Journal of Chromatography A, April 1980, Elsevier

    Dr. Karen Bush

  101. Izumenolide - a novel .BETA.-lactamase inhibitor produced by Micromonospora. II. Biological properties.

    Article • The Journal of Antibiotics, January 1980, Japan Antibiotics Research Association

    Dr. Karen Bush

  102. Deuterium isotope effects on initial rates of the liver alcohol dehydrogenase reaction. V

    Article • Biochemistry, November 1973, American Chemical Society (ACS)

    Dr. Karen Bush

  103. Chymotrypsin catalysis. Evidence for a new intermediate, III

    Article • Journal of the American Chemical Society, April 1973, American Chemical Society (ACS)

    Dr. Karen Bush

  104. Isotope and solvent effects of deuterium on aconitase

    Article • Archives of Biochemistry and Biophysics, October 1966, Elsevier

    Dr. Karen Bush